138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Catherine Thiéblemont(Université Paris Cité), Nathan Fowler(Repligen (United States)), Peter A. Riedell(University of Chicago), Jason Butler(Oslo University Hospital), P. Joy Ho(The University of Sydney), Rafael Jacques Ramos(Novartis (United States)), Ram Malladi(Cambridge University Hospitals NHS Foundation Trust), Koji Kato(AbbVie (United States)), M. J. Kersten(Amsterdam University Medical Centers), Takanori Teshima(Hokkaido University Hospital), Monalisa Ghosh(Michigan Medicine), A. Chen(Oregon Health & Science University), Piers Patten, Joseph P. McGuirk(University of Kansas Medical Center), Emmanuel Bachy(Université Claude Bernard Lyon 1), Andreas Viardot(University Hospital Ulm), Aiesha Zia(Novartis (Switzerland)), L. Nastoupil(The University of Texas MD Anderson Cancer Center), M. Dreyling(LMU Klinikum), Stephen J. Schuster(Hospital of the University of Pennsylvania), Hideo Harigae(Tohoku University Hospital), Julio C. Chávez(Moffitt Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Arne Kolstad(Oslo University Hospital), C. Andreadis(University of California, San Francisco), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Michael Dickinson(The University of Melbourne), Domenico Germano, R. Awasthi(Novartis (United States)), Fritz Offner(Ghent University Hospital), Peihong Hsu(Novartis (Switzerland)), B. vonTresckow(University of Cologne), Leslie Popplewell(City Of Hope National Medical Center)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859